Analysis of pathogenic roles of MuSK antibodies in myasthenia gravis using the experimental animal models.

利用实验动物模型分析MuSK抗体在重症肌无力中的致病作用。

基本信息

项目摘要

We have provided the evidence that active immunization with MuSK protein reproduces myasthenia gravis in animals. Next we focus on how MuSK antibodies cause MG. The pathogenic roles of MuSK antibodies in MG have been questioned as the number of AChRs is not reduced and complement is not deposited at the NMJ of biceps brachii muscles MuSK-positive patients with MG. The mechanisms of MG caused by AChR antibodies are well delineated, but the revealed mechanisms are not able to simply apply to MG with MuSK antibodies. MuSK antibodies have been identified as predominantly IgG4 subclass, which does not activate complement. We found that agrin-induced clustering of AChR was strongly blocked in the presence of MuSK antibodies, whereas absorption of the antibodies with purified MuSK products prevented this blocking effect. These results showed that the MuSK antibodies effectively inhibited the formation of agrin-induced AChR clustering. Intriguingly, the monovalent Fab fragments of MuSK antibodies from rabbits with EAMG also inhibited AChR clustering by agrin on C2C12 cells, indicating that complement-mediated mechanisms are not necessarily required for such inhibition. We then examined the reduced expression of AChR at NMJ in soleus muscles of paretic and normal rabbits by fluorescence microscopy. In addition, the structure of NMJ in our paretic rabbits, as well as the size and branching of the motor terminals, were significantly reduced. Electron microscopic observations of NMJ in rabbits with EAMG induced by injection of MuSK protein demonstrated a significant loss of complexity of convoluted synaptic folds but no destruction, and EAMG model cited here resembles the phenotype of humans with MG and MuSK antibodies. Our results showed that MuSK antibodies inhibit both anterograde and retrograde signals required for maintaining the synaptic structures in mature NMJ.
我们已经提供了用MuSK蛋白主动免疫在动物中复制重症肌无力的证据。接下来我们关注MuSK抗体如何引起MG。MuSK抗体在MG中的致病作用受到质疑,因为AChR的数量没有减少,并且补体没有沉积在MuSK阳性MG患者的肱二头肌NMJ处。AChR抗体引起MG的机制已得到很好的描述,但所揭示的机制并不能简单地适用于MuSK抗体引起的MG。MuSK抗体已被鉴定为主要的IgG4亚类,其不激活补体。我们发现,在MuSK抗体的存在下,聚集蛋白诱导的AChR聚集被强烈阻断,而用纯化的MuSK产品吸收抗体阻止了这种阻断作用。这些结果表明,MuSK抗体有效地抑制了聚集蛋白诱导的AChR聚集的形成。有趣的是,来自患有EAMG的兔的MuSK抗体的单价Fab片段也抑制C2C12细胞上聚集蛋白引起的AChR聚集,这表明补体介导的机制不一定是这种抑制所必需的。然后,我们研究了减少表达的乙酰胆碱受体在NMJ在比目鱼肌麻痹和正常兔通过荧光显微镜。此外,在我们的麻痹兔的NMJ的结构,以及运动终末的大小和分支,显着减少。注射MuSK蛋白诱导的EAMG家兔NMJ的电镜观察表明,回旋突触折叠的复杂性显著丧失,但没有破坏,这里引用的EAMG模型类似于MG和MuSK抗体的人的表型。我们的研究结果表明,MuSK抗体抑制顺行和逆行信号所需的维持成熟NMJ的突触结构。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
神経筋シナプス形成、維持、再生の分子機構の解明(重症筋無力症の分子病態についての新しい展開)
阐明神经肌肉突触形成、维持和再生的分子机制(重症肌无力分子病理学新进展)
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Mikuni N;Ohara S;Ikeda A;Hayashi N;Nishida N;Taki J;Enatsu R;Matsumoto R;Shibasaki H;Hashimoto N;重本和宏
  • 通讯作者:
    重本和宏
MuSK(Muscle-specific kinase)とは
什么是 MuSK(肌肉特异性激酶)?
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    重本和宏;太田光熙
  • 通讯作者:
    太田光熙
特集免疫性神経・筋疾患の動物モデル.
特色:免疫介导的神经肌肉疾病的动物模型。
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    安田幸代;矢野育子;橋田亨;木下真幸子;池田昭夫;高橋良輔;乾賢一;重本和宏
  • 通讯作者:
    重本和宏
Anti-alkaline phosphatase antibody positive myasthenia gravis.
抗碱性磷酸酶抗体阳性重症肌无力。
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Konishi T;Ohta K;Shigemoto K & Ohta M.
  • 通讯作者:
    Shigemoto K & Ohta M.
Experimentally induced myasthenia gravis with muscle-specific kinase.
通过肌肉特异性激酶实验诱导重症肌无力。
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SHIGEMOTO Kazuhiro其他文献

SHIGEMOTO Kazuhiro的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SHIGEMOTO Kazuhiro', 18)}}的其他基金

Elucidation of metabolic shift of skeletal muscle during aging and invention of new therapies for sarcopenia
阐明衰老过程中骨骼肌的代谢变化并发明肌肉减少症新疗法
  • 批准号:
    25670437
  • 财政年份:
    2013
  • 资助金额:
    $ 2.57万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Elucidation of pathogenic mechanisms of myasthenia gravis caused by MuSK antibodies using a new synchronized experimental animal model
使用新的同步实验动物模型阐明MuSK抗体引起的重症肌无力的致病机制
  • 批准号:
    21591102
  • 财政年份:
    2009
  • 资助金额:
    $ 2.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Elucidation of the molecular mechanisms of muscle atrophy
阐明肌肉萎缩的分子机制
  • 批准号:
    21200023
  • 财政年份:
    2009
  • 资助金额:
    $ 2.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research on Innovative Areas (Research a proposed research project)
Analysis of MuSK functions and the molecular pathogenesis of myasthenia gravis with anti-MuSK autoantibodies by proteomic approaches
通过蛋白质组学方法分析 MuSK 功能和抗 MuSK 自身抗体重症肌无力的分子发病机制
  • 批准号:
    14580745
  • 财政年份:
    2002
  • 资助金额:
    $ 2.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Examining Links between General Fatigue in Myasthenia Gravis with Objectively Measured Sleep
检查重症肌无力的全身疲劳与客观测量的睡眠之间的联系
  • 批准号:
    480775
  • 财政年份:
    2023
  • 资助金额:
    $ 2.57万
  • 项目类别:
Wearable Sensor and Digital Technologies for Quantitative Assessment and Remote Monitoring of Symptoms in Myasthenia Gravis
用于定量评估和远程监测重症肌无力症状的可穿戴传感器和数字技术
  • 批准号:
    10757163
  • 财政年份:
    2023
  • 资助金额:
    $ 2.57万
  • 项目类别:
MV2C2 antibody as a new therapeutic for Myasthenia Gravis
MV2C2 抗体作为重症肌无力的新疗法
  • 批准号:
    10546538
  • 财政年份:
    2022
  • 资助金额:
    $ 2.57万
  • 项目类别:
Bruton's tyrosine kinase as a novel target of treatment for myasthenia gravis
布鲁顿酪氨酸激酶作为治疗重症肌无力的新靶点
  • 批准号:
    22K20892
  • 财政年份:
    2022
  • 资助金额:
    $ 2.57万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Wearable Sensor and Digital Technologies for Quantitative Assessment and Remote Monitoring of Symptoms in Myasthenia Gravis
用于定量评估和远程监测重症肌无力症状的可穿戴传感器和数字技术
  • 批准号:
    10470564
  • 财政年份:
    2022
  • 资助金额:
    $ 2.57万
  • 项目类别:
Novel pathogenesis of myasthenia gravis: immune checkpoint molecules and complements regulatory molecules and their development into therapy
重症肌无力的新发病机制:免疫检查点分子和补充调节分子及其发展为治疗
  • 批准号:
    21K07421
  • 财政年份:
    2021
  • 资助金额:
    $ 2.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Basic research for development of a new drug for the treatment of myasthenia gravis
治疗重症肌无力新药开发的基础研究
  • 批准号:
    21H02614
  • 财政年份:
    2021
  • 资助金额:
    $ 2.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Examining Links between General Fatigue in Myasthenia Gravis with Objectively Measured Sleep
检查重症肌无力的全身疲劳与客观测量的睡眠之间的联系
  • 批准号:
    466591
  • 财政年份:
    2021
  • 资助金额:
    $ 2.57万
  • 项目类别:
    Studentship Programs
Induction of a mouse model of myasthenia gravis by acetylcholine receptor site-specific autoantibody production.
通过乙酰胆碱受体位点特异性自身抗体的产生诱导重症肌无力小鼠模型。
  • 批准号:
    20K07766
  • 财政年份:
    2020
  • 资助金额:
    $ 2.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Autologous T-cells Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen (BCMA) in patients with Generalized Myasthenia Gravis (MG)
全身性重症肌无力 (MG) 患者中表达针对 B 细胞成熟抗原 (BCMA) 的嵌合抗原受体的自体 T 细胞
  • 批准号:
    10010086
  • 财政年份:
    2020
  • 资助金额:
    $ 2.57万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了